Stavudine plasma concentrations and lipoatrophy

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 933-938

  ter Hofstede, Hadewych J M ^a   Koopmans, Peter P ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV infection; Nucleoside reverse transcriptase inhibitors; Pharmacokinetics; Stavudine serum levels

Indexed keywords

DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA; RETROSPECTIVE STUDIES; STAVUDINE; TIME FACTORS;

EID: 41149097672     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn041     Document Type: Article

References (44)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
2. WHO. Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents. http://www.who.int/hiv/art/ ARTadultsaddendum.pdf (25 January 2008, date last accessed).
3. WHO. WHO Project: ICP HIV 001. The Use of Antiretroviral Therapy: A Simplified Approach for Resource-Constrained Countries. http://www.searo.who.int/LinkFiles/Publications_aids-133.pdf (25 January 2008, date last accessed).
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
5. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
6. Mallal SA, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
7. Saint-Marc T, Partisani M, Poizot-Martin et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
8. Gatti G, Di BA, Casazza R et al. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS 1999; 13: 2083-9.
9. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
10. Rodriguez NS, Barreiro P, Rendon A et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gone 1. Clin Infect Dis 2006; 42: 291-5.
11. Dicenzo R, Luque A, Larppanichpoonphol P et al. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother 2006; 58: 393-400.
12. Gutierrez F, Navarro A, Padilla S et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41: 1648-53.
13. Fletcher CV, Anderson PL, Kakuda TN et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16: 551-60.
14. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30 Suppl 2: S135-42.
15. Carr A, Miller J, Law M et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-32.
16. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27: 237-44.
17. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-9.
18. Dieleman JP. Risk of lipodystrophy is highest after prolonged exposure to stavudine containing antiretroviral treatment. The ATHENA cohort. 108-22. Thesis 2003.
19. Carr A, Emery S, Law M et al. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-35.
20. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33: 571-6.
21. Horton CM, Dudley MN, Kaul S et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39: 2309-15.
22. Verweij-van Wissen CP, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Anlyt Technol Biomed Life Sci 2005; 814: 121-9.
23. Fletcher CV, Kawle SP, Kakuda TN et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000; 14: 2137-44.
24. Fletcher CV, Acosta EP, Henry K et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64: 331-8.
25. Kim RB. Drug transporters in HIV Therapy. Top HIV Med 2003; 11 136-9.
26. Acosta EP, Kakuda TN, Brundage RC et al. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 Suppl 2: S151-9.
27. Gandhi M, Aweeka F, Greenblatt RM et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499-523.
28. Angel JB, Khaliq Y, Monpetit ML et al. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS 2001; 15: 417-9.
29. Sanchez-Conde M, de MC, Jimenez-Nacher I et al. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6: 197-202.
30. Hanvanich M, Prasanthai V, Riengschan R et al. Reduction of d4T dosage improves lipoatrophy without virological failure. Antivir Ther 2003; 8: S392-3.
31. Hill A, Ruxrungtham K, Hanvanich M et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8: 679-88.
32. Milinkovic A, Martinez E, López S et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12: 407-15.
33. Burger DM, Hugen PW, Aarnoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
34. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
35. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
36. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-65.
37. Bossi P, Peytavin G, Ait-Mohand H et al. GENOPHAR: A randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5: 352-9.
38. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37 Suppl 1: S2-12.
39. Burger DM, Aarnoutse RE, Hugen PW. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002; 15: 17-22.
40. Burger DM, Hoetelmans RM, Koopmans PP et al. Clinically relevant drug interactions with antiretroviral agents. Antivir Ther 1997; 2: 149-65.
41. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-7.
42. Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-9.
43. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005; 28: 1075-83.
44. Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV-infection. J Clin Virol 2003; 27: 117-28.